Coral reefs are often celebrated for their colorful fish and intricate structures, but beneath the surface lies an even more complex world: the microbial communities living inside and around corals. A new study from the Tara Pacific expedition has now mapped this hidden diversity at an unprecedented scale, revealing that coral microbiomes are vast reservoirs of unknown genomic and biosynthetic potential.

The research team collected coral fragments and seawater samples from 99 reefs across 32 islands in the Pacific Ocean. They focused on four major coral genera—*Pocillopora*, *Porites*, *Millepora*, and *Heliopora*—and gathered seawater from three distinct niches: open ocean, reef water, and water directly surrounding corals. DNA was extracted from these samples and sequenced using Illumina NovaSeq6000 and HiSeq4000 platforms, generating around 100 million 150-base-pair paired-end reads per sample.

By combining this new data with publicly available coral and sponge microbiome datasets, the researchers built what they call the Reef Microbiome Database, or RMD. This resource now contains over 2,900 high-quality metagenome-assembled genomes, or MAGs, from coral-associated microbes. Of these, more than 2,000 represent previously unknown species—microbes that science has never seen before. Many of these genomes belong to groups like *Candidatus* *Thiosymbion*, *Candidatus* *Magnetobacterium*, and *Candidatus* *Endobugula*, which are known for their specialized roles in marine ecosystems but whose full diversity was largely uncharted.

The study also uncovered a striking pattern: the microbes living inside corals—the endolithic community—are far more diverse and distinct from those in surrounding seawater than previously thought. This suggests that corals are not just hosts but active architects of their own microbial ecosystems. Moreover, the biosynthetic gene clusters found in these genomes hint at a treasure trove of natural products, from novel antibiotics to bioactive compounds, that could have applications in medicine and biotechnology.

What makes this work especially powerful is that the RMD is now a publicly available resource. Researchers worldwide can use it to profile coral microbiomes at species-level resolution, track changes over time, and even discover new microbial functions. As coral reefs face mounting threats from climate change and pollution, this genomic atlas offers both a scientific foundation and a conservation tool—highlighting that protecting reefs means safeguarding an immense, hidden world of microbial life.

[[TRANSITION]]

Here's a deep-dive segment based on the provided information:

Choanoeca flexa, a marine choanoflagellate, has been discovered to exhibit a remarkable ability to form multicellular structures through three distinct developmental modes - purely clonal, purely aggregative, or a combination of both - depending on environmental salinity conditions.

This finding is particularly significant because it challenges our understanding of how multicellularity evolved. Choanoflagellates are considered the closest living relatives of animals, making them crucial for understanding the origins of animal multicellularity. The ability of C. flexa to switch between different modes of multicellular development suggests that early animal ancestors may have had similar developmental plasticity.

The multicellular structures formed by C. flexa are described as motile and contractile cell monolayers. These structures can form through complete clonal development, where all cells descend from a single founder cell, or through complete aggregation, where previously independent cells come together. In intermediate conditions, both processes occur simultaneously.

What makes this discovery especially intriguing is that the developmental mode is environmentally tuned. Salinity appears to be the key environmental factor controlling whether C. flexa develops clonally, aggregatively, or through a mixed mode. This environmental sensitivity suggests that early multicellular organisms may have been able to adapt their developmental strategies based on environmental conditions.

The contractile nature of these monolayers is also noteworthy, as it resembles the contractile tissues found in animals. This similarity provides insights into how early contractile tissues might have evolved and how they could have contributed to the emergence of more complex animal body plans.

This research fundamentally changes our understanding of choanoflagellate biology and provides new perspectives on the evolutionary transitions that led to animal multicellularity. The ability to form multicellular structures through multiple developmental pathways suggests that the evolution of animal multicellularity may have been more flexible and environmentally responsive than previously thought.

[[TRANSITION]]

Here's a deep-dive segment based on the provided information:

CAR-NK cell therapies have shown promise for treating blood cancers, but solid tumors have remained a stubborn challenge. A new study published in Nature introduces a clever engineering strategy that could change that. Researchers have identified what they call "boosters" - genetic elements that can be built directly into CAR constructs to dramatically increase gene expression in NK cells.

The key innovation centers on OR7A10, an olfactory receptor that the team repurposed as a booster. When incorporated into CAR designs, OR7A10 drives much higher levels of CAR expression on the NK cell surface compared to conventional constructs. This matters because solid tumors present unique obstacles - they're often large, poorly vascularized, and can suppress immune responses. Having more CAR molecules on each NK cell means stronger anti-tumor activity.

The approach is elegantly simple: rather than trying to optimize complex manufacturing protocols or find rare NK cell subsets, the researchers just modified the genetic payload itself. The booster elements work across different CAR designs and target antigens, suggesting this could be a general strategy for improving NK cell therapies.

In preclinical models, the boosted CAR-NK cells showed markedly improved tumor control compared to standard versions. The enhanced expression translated to better persistence in the tumor microenvironment and more sustained anti-cancer activity.

What makes this particularly exciting is the scalability. Since the boosters are built into the CAR construct, the same manufacturing process used for conventional CAR-NK cells should work - just with better results. This could accelerate development of NK cell therapies for solid tumors, which have been difficult to treat with existing approaches.

The researchers note this strategy could extend beyond NK cells to other immune cell therapies where robust transgene expression is critical for efficacy.

[[TRANSITION]]

This paper from Nature's Protein Design journal introduces a novel approach to data storage using unnatural proteins expressed in E. coli bacteria. The research team has developed a system where digital information can be encoded into protein sequences, which are then produced by engineered bacteria. This represents a significant advancement in biocomputing and data storage technology, potentially offering a biological alternative to traditional silicon-based storage methods.

The core innovation appears to involve designing proteins with specific amino acid sequences that can represent binary data. By leveraging the natural protein synthesis machinery of E. coli, the researchers can create large quantities of these data-encoded proteins. The system likely uses a combination of standard and non-standard amino acids to expand the coding capacity beyond what natural proteins can achieve.

What makes this approach particularly interesting is the potential for extremely dense data storage. Proteins are incredibly compact molecules, and if the encoding scheme is efficient, this could allow for storing vast amounts of information in very small physical volumes. The use of E. coli as a production platform also suggests the possibility of scalable, self-replicating data storage systems.

The technology could have applications in areas where traditional storage methods are impractical, such as long-term archival storage or extreme environments where electronic devices might fail. Additionally, the biological nature of the storage medium could offer advantages in terms of energy efficiency and durability.

However, the available text doesn't provide details on the specific encoding scheme, data retrieval methods, or the current storage density achieved. The competing interests section notes that several authors are inventors on a patent application for this technology, indicating its potential commercial value. The paper is published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, allowing for broad sharing of the research while protecting the authors' intellectual property rights.

[[TRANSITION]]

Intermittent fasting, the practice of cycling between periods of eating and fasting, has been widely studied for its potential health benefits, including metabolic improvements and longevity. However, a new study published in Nature reveals a surprising downside: intermittent fasting can disrupt the body's long-term immune memory by evicting long-lived plasma cells from their survival niche in the bone marrow.

Long-lived plasma cells are a critical component of humoral immunity. Unlike short-lived plasma cells that respond immediately after infection or vaccination, LLPCs persist for months or even years in the bone marrow. They continuously secrete antibodies, providing durable protection against pathogens the body has encountered before. These cells rely on a specialized microenvironment—often called a survival niche—composed of stromal cells, cytokines like APRIL and BAFF, and adhesion molecules that anchor them in place.

The study used mouse models to investigate how intermittent fasting affects this system. When mice were subjected to fasting regimens, researchers observed a significant reduction in the number of LLPCs residing in the bone marrow. This eviction from their niche led to a marked decline in protective antibody levels, suggesting that the maintenance of long-term humoral immunity was impaired.

The mechanism appears to involve metabolic changes triggered by fasting. Fasting alters the availability of nutrients and growth factors in the bone marrow microenvironment, which in turn disrupts the signaling pathways that normally keep LLPCs anchored. Without these signals, LLPCs detach from their niche and undergo apoptosis, effectively erasing part of the immune system's memory.

This finding is particularly relevant for people who practice intermittent fasting for health reasons. While fasting may offer metabolic and cellular benefits, it could come at the cost of weakening long-term antibody responses. This is especially concerning for individuals who rely on robust humoral immunity, such as the elderly or those with compromised immune systems.

The study also raises questions about the timing of fasting relative to vaccination. If fasting can reduce LLPC numbers, it might be wise to avoid prolonged fasting periods immediately after receiving vaccines that aim to establish long-term protection.

In summary, while intermittent fasting has many documented benefits, this research highlights an important trade-off: the eviction of long-lived plasma cells from their bone marrow niche can impair the maintenance of protective antibodies. This underscores the need for a balanced approach to fasting, particularly for those prioritizing long-term immune memory.

[[TRANSITION]]

A new study in Protein Science reveals that the endoplasmic reticulum plays a crucial role in guiding proteins to mitochondria in neurons. Researchers found that ER-mitochondria contact sites act as key hubs for protein targeting, with specific ER proteins helping shuttle mitochondrial precursors across the cellular landscape. This discovery sheds light on how neurons maintain their high energy demands through precise organelle communication. The findings could have implications for understanding neurodegenerative diseases where protein trafficking goes awry. The study highlights the importance of ER-mitochondria crosstalk in neuronal health and function.

[[TRANSITION]]

Researchers studying a computationally designed miniprotein have uncovered a previously elusive chemical modification: the spontaneous conversion of aspartate residues into isoaspartate through deamidation and isomerization. This finding, reported in Protein Science, highlights an unexpected vulnerability in engineered proteins that could impact their stability and function in therapeutic and research applications. The study used temperature-dependent nuclear magnetic resonance and molecular dynamics simulations to track these subtle structural changes over time. Isoaspartate formation can alter protein folding and binding properties, raising important considerations for the long-term reliability of de novo designed proteins. The work underscores the need to account for such post-translational modifications when designing stable, functional miniproteins for biomedical use.

[[TRANSITION]]

Researchers have developed MemPPI, a new platform for measuring and engineering membrane protein-protein interactions in mammalian cells using split nanoluciferase. This tool addresses the challenge of systematically quantifying how transmembrane domains interact laterally within cell membranes. Membrane protein interactions are crucial for signal transduction, transport, and cell communication, but existing methods have struggled to capture these dynamics in living cells. MemPPI enables researchers to both measure and manipulate these interactions with greater precision, potentially advancing our understanding of membrane biology and opening new avenues for therapeutic development targeting membrane proteins. The platform represents a significant step forward in studying the complex world of membrane protein interactions in their native cellular context.

[[TRANSITION]]

A new computational approach combining molecular dynamics with proteome-wide screening has uncovered high-affinity hepatitis B virus T-cell epitopes that conventional sequence-based methods missed. Published in Protein Science, the study shows that integrating dynamic structural modeling with traditional binding predictions dramatically improves the identification of potent epitopes for vaccine design. This method overcomes a major bottleneck in T-cell immunotherapy development by providing more accurate quantitative rankings of candidate epitopes. The findings could accelerate the design of targeted HBV vaccines and other T-cell-based treatments by ensuring only the most immunologically effective epitopes are prioritized for further development.

[[TRANSITION]]

The rapid emergence of SARS-CoV-2 variants with spike protein mutations is undermining the effectiveness of current vaccines, and that's driving researchers to explore new strategies for broad and lasting immunity. In this study, scientists used immunoinformatics to design two multi-epitope vaccine constructs—Cov19-B and Cov19-T—targeting the most notable mutations in the spike protein.

Cov19-B is a 649-amino-acid protein weighing about 74 kilodaltons, while Cov19-T is smaller at 465 amino acids. Both were built by identifying conserved and variant-specific epitopes—short amino acid sequences that can trigger immune responses—across multiple SARS-CoV-2 variants. The team used computational tools to predict which epitopes would be most likely to bind to human leukocyte antigens, or HLAs, which are crucial for presenting antigens to T cells. They also screened for epitopes that could stimulate both B cell and T cell immunity, aiming for a vaccine that could provoke a strong and durable response.

One of the key innovations here is the focus on spike protein mutations that have arisen in variants of concern. By incorporating epitopes from both conserved regions and mutation hotspots, the researchers hoped to create a vaccine that could recognize not just current strains but also potential future variants. The constructs were also designed with adjuvants—molecular helpers that boost immune activation—and linkers to ensure proper folding and presentation of the epitopes.

The available text does not provide details on the specific mutations targeted, nor does it report experimental validation results such as immune response data or efficacy in animal models. However, the approach represents a shift toward more adaptable vaccine design, using computational prediction to stay ahead of viral evolution. If validated experimentally, such multi-epitope vaccines could offer broader protection and reduce the need for frequent updates as the virus continues to mutate.

[[TRANSITION]]

Graph Neural Networks have emerged as a central methodology for modeling biological systems where entities and their interactions form inherently non-Euclidean structures. From protein interaction networks and gene regulatory circuits to molecular graphs and multi-omics integration, the relational nature of biological data makes GNNs particularly well-suited for capturing complex dependencies that traditional machine learning approaches struggle to represent.

The fundamental innovation of GNNs lies in their ability to operate directly on graph-structured data. Unlike conventional neural networks that assume grid-like input structures, GNNs can process data where relationships between entities are as important as the entities themselves. This capability has proven transformative for bioinformatics, where biological systems are naturally represented as networks of interacting components.

In protein science, GNNs have enabled researchers to model protein structures as graphs where amino acids are nodes and their spatial proximities or chemical interactions form edges. This representation allows the network to learn how local structural features propagate to influence global protein function. Similarly, gene regulatory networks can be modeled with genes as nodes and regulatory relationships as edges, enabling the discovery of functional modules and regulatory patterns that would be difficult to identify through traditional statistical methods.

The survey highlights several key architectural innovations in GNNs that have proven particularly valuable for biological applications. Message passing neural networks, for instance, allow information to propagate through the graph structure, enabling nodes to aggregate information from their neighbors iteratively. This mechanism mirrors how biological signals often propagate through networks of interacting molecules or cells.

Attention mechanisms have also been integrated into GNN architectures, allowing the model to learn which relationships are most important for specific prediction tasks. This is particularly valuable in biological contexts where not all interactions are equally relevant for a given function or phenotype.

Multi-omics integration represents another frontier where GNNs have shown promise. By constructing graphs that connect different types of biological data - such as genomics, transcriptomics, and proteomics - researchers can capture the complex interplay between different molecular layers that underlies biological function and disease.

The survey also addresses challenges specific to applying GNNs in bioinformatics. Biological graphs often exhibit properties like high sparsity, heterogeneity in node and edge types, and dynamic changes over time. Additionally, the interpretability of GNN predictions remains an active area of research, as understanding why a model makes certain predictions is crucial for biological discovery and clinical applications.

Despite these challenges, the review demonstrates that GNNs have already enabled significant advances across multiple bioinformatics domains. From predicting protein functions and drug-target interactions to identifying disease-associated genes and understanding cellular organization, GNN-based approaches are providing new insights into the complex networks that underlie biological systems.

The available text does not provide specific performance metrics or comparative analyses with traditional methods, but the survey emphasizes that GNNs have become a standard tool in the bioinformatics toolkit, with applications spanning from fundamental biological research to translational medicine and drug discovery.

[[TRANSITION]]

Monoclonal antibodies are the backbone of modern biopharmaceuticals, but their production is far from straightforward. While these proteins are prized for their high specificity and relatively low side effects, the purification process—especially chromatography—can actually damage them. That's the central finding of a comprehensive review published in the International Journal of Molecular Sciences, which examined over two decades of research on how chromatographic steps can induce conformational instability in monoclonal antibodies.

The review, which analyzed studies from 2000 to 2025, found that the very conditions that make chromatography effective for separation—like high salt concentrations, extreme pH shifts, and the physical microenvironment of resin surfaces—can also trigger protein unfolding, self-association, and aggregation. These aren't just academic concerns. Conformational changes can reduce the therapeutic efficacy of mAbs, increase manufacturing costs due to product loss, and even raise the risk of immunogenicity in patients.

What's particularly striking is that these effects aren't uniform across all chromatographic methods. Affinity chromatography, often used for its high selectivity, can expose mAbs to harsh elution conditions. Ion exchange and hydrophobic interaction chromatography can induce stress through pH and ionic strength variations. Even multimodal chromatography, designed to be gentler, isn't immune if process parameters aren't carefully controlled.

The review also highlights a critical gap: while many studies report separation performance, far fewer actually assess the structural integrity of the protein post-purification. This means the industry may be overlooking subtle but significant quality issues. The authors call for more routine use of analytical tools—like circular dichroism, dynamic light scattering, and size exclusion chromatography—during process development to catch these problems early.

In short, the review makes a compelling case that chromatographic purification, while essential, is a double-edged sword for mAb manufacturing. Without careful monitoring and optimization, the very steps meant to ensure purity could be undermining the stability and safety of these life-saving drugs.

[[TRANSITION]]

PIM kinases are serine/threonine kinases that regulate key cellular processes like proliferation, apoptosis, and metabolism by phosphorylating multiple substrates. Because of this central role, they've become important therapeutic targets for cancer treatment.

In this study, researchers set out to design novel PIM-1 kinase inhibitors using a scaffold-hopping strategy. They started from the Amgen compound C28, which had a quinazolinone core structure. By analyzing the PIM-1/C28 co-crystal structure, they identified opportunities to modify the scaffold while maintaining key binding interactions.

The design strategy involved a ring-opening of the quinazolinone followed by a ring-closing operation between the benzene and pyrrole rings. This created a new pyrroloquinoline scaffold that maintained the essential pharmacophore elements needed for PIM-1 binding but with a completely different core structure.

They synthesized three series of compounds: A1 through A5, B1 through B8, and C1 through C8. The synthesis involved multi-step organic reactions including Suzuki coupling, ring-closing reactions using DMF-DMA or triphosgene, ester hydrolysis, and amidation steps.

The most promising compound from this series was C2. In kinase assays, C2 showed high potency with an IC50 of 33.02 ± 1.31 nM against PIM-1. This represents a significant improvement over the starting scaffold.

Beyond kinase inhibition, C2 demonstrated favorable in vitro antitumor activity. Against the MM.1S hematological tumor cell line, it showed an IC50 of 1.87 μM. This suggests the compound not only inhibits the target kinase effectively but also translates that inhibition into meaningful cellular effects.

The scaffold-hopping approach successfully generated structurally novel PIM-1 inhibitors with improved potency compared to the starting scaffold, demonstrating how computational design strategies can lead to new chemical matter with enhanced biological activity.

[[TRANSITION]]

Peptide-functionalized nanoparticles are emerging as a promising strategy to overcome the blood-brain barrier and deliver drugs directly to the brain. Despite rapid advances in nanoparticle-based drug delivery systems, getting therapeutics past the brain's protective barriers remains a major challenge. The blood-brain barrier, along with the blood-cerebrospinal fluid barrier and brain-cerebrospinal fluid barrier, tightly regulates what can enter the central nervous system. For a drug to be effective, it must not only avoid being trapped in off-target organs but also selectively reach the brain, cross these barriers, and accumulate at the right sites.

To address this, researchers are turning to peptides—short chains of amino acids—that can be attached to the surface of nanoparticles. These peptides act like molecular keys, helping the nanoparticles navigate biological barriers and target specific brain regions. Some of the most studied peptides include RVG29, T7, Angiopep-2, and mApoE. Each of these has unique properties that make it useful for different aspects of brain targeting. For example, RVG29 is derived from the rabies virus and can bind to receptors on neurons, while Angiopep-2 can interact with receptors that are highly expressed at the blood-brain barrier.

The process of functionalizing nanoparticles with these peptides involves careful design and synthesis. Researchers must ensure that the peptides are stably attached to the nanoparticle surface and that they retain their targeting ability once delivered. This often involves chemical conjugation techniques and rigorous testing to confirm that the peptides do not lose their function during the process.

The advantages of using peptide-functionalized nanoparticles are significant. They can improve the selectivity and efficiency of drug delivery, reduce side effects by minimizing off-target accumulation, and potentially enable the delivery of drugs that were previously unable to reach the brain. However, there are still challenges to overcome, such as ensuring the stability of the peptides in the body, avoiding immune responses, and scaling up

[[TRANSITION]]

When the COVID-19 vaccines rolled out, they represented a massive real-world experiment in human immunology. For the first time, billions of people were exposed to the same viral antigen through different delivery platforms. But until now, no one had directly compared all three FDA-approved vaccines at the single-cell level to see exactly how each one shapes the immune response.

This new study from JCI Insight does exactly that. Researchers tracked immune responses in people who received either the Pfizer-BioNTech or Moderna mRNA vaccines, or the Johnson & Johnson adenovirus-based vaccine. They collected blood samples at multiple timepoints—before vaccination, after the first dose, and after the second dose for the mRNA vaccines—and analyzed them using single-cell RNA sequencing and other multiomic techniques.

What they found was striking. The mRNA vaccines triggered a strong, coordinated interferon response in myeloid cells—specifically monocytes and dendritic cells. This interferon program peaked after the first dose and then tapered off, but it left behind a trained immune state. The adenovirus vaccine, by contrast, produced a more muted interferon signature and relied more heavily on other innate immune pathways.

The dose also mattered. Higher RNA doses in the Moderna vaccine correlated with stronger and longer-lasting interferon signatures compared to Pfizer's lower dose. This suggests that the amount of antigen or RNA delivered can tune the innate immune activation, which in turn shapes the adaptive response.

These differences may explain why some people experience stronger side effects with one vaccine over another, and why the durability of protection varies. The interferon response is known to enhance antigen presentation and prime T and B cell responses, so a stronger early signal could lead to better long-term immunity.

This study is the first to map these vaccine-specific immune programs at such high resolution. It shows that even when vaccines target the same antigen, the platform and dose can create fundamentally different immune trajectories. That's a crucial insight for designing future vaccines—not just for COVID-19, but for any pathogen where rapid, durable protection is needed.

[[TRANSITION]]

Liver fibrosis is a major health problem where chronic liver injury leads to excessive scarring and loss of function. One promising therapeutic approach involves using engineered macrophages—specifically chimeric antigen receptor macrophages, or CAR-Ms—to target and eliminate the activated hepatic stellate cells that drive fibrosis. But there's a catch: in the fibrotic environment, these CAR-Ms tend to adopt a pro-inflammatory phenotype, which actually undermines their ability to resolve fibrosis.

To address this, researchers developed a new strategy to reprogram CAR-Ms to be more anti-inflammatory while still retaining their ability to kill activated stellate cells. The key innovation is the use of a specially designed lipid nanoparticle that can deliver mRNA encoding both the CAR and an anti-inflammatory protein called TRIM13 directly to macrophages inside the fibrotic liver.

The nanoparticles are made from a novel ionizable lipid called PnT14, paired with a helper lipid called PST. PST is engineered to expose phosphatidylserine—a lipid normally found on the inner leaflet of cell membranes—when it encounters the high levels of reactive oxygen species (ROS) present in fibrotic tissue. This ROS-triggered exposure of PS helps the nanoparticles selectively bind to and enter macrophages in the fibrotic niche.

Once inside, the nanoparticles release their mRNA cargo, enabling the macrophages to produce both the CAR for targeting activated stellate cells and TRIM13, which shifts the macrophages toward an anti-inflammatory, tissue-repairing phenotype. This dual effect—targeted killing of fibrogenic cells plus reduced inflammation—leads to more effective resolution of liver fibrosis in experimental models.

The approach represents a significant advance because it overcomes the limitation of CAR-Ms' inflammatory bias in fibrotic environments, using a smart delivery system that responds to the disease microenvironment. By reprogramming macrophages in situ, this method could make CAR-M therapy much more effective for treating liver fibrosis and potentially other fibrotic diseases.

[[TRANSITION]]

Rheumatoid arthritis and type 2 diabetes mellitus are both chronic inflammatory diseases that have been increasingly recognized as sharing pathogenic pathways. This study set out to uncover the molecular overlap between the two conditions using integrated transcriptomic and bioinformatic analyses, with the ultimate goal of identifying new therapeutic strategies through drug repositioning.

The researchers began by collecting gene expression data from publicly available datasets, focusing on peripheral blood mononuclear cells from patients with RA, T2DM, and healthy controls. They performed differential expression analysis to identify genes that were consistently dysregulated across both diseases. This led to the identification of a set of shared differentially expressed genes, which were then subjected to functional enrichment analysis.

The functional analysis revealed that these shared genes were significantly enriched in inflammatory and immune-related pathways, including cytokine signaling, NF-κB signaling, and T cell activation. This aligns with the known role of chronic inflammation in both RA and T2DM pathogenesis. The study also identified key transcription factors and upstream regulators that may drive the co-expression of these genes in both diseases.

To explore therapeutic potential, the researchers used network-based drug repositioning approaches. They mapped the shared gene signatures onto protein-protein interaction networks and identified existing drugs that could potentially target these networks. Several drugs already approved for other indications emerged as candidates, including some anti-inflammatory agents and metabolic modulators.

The study highlights the power of integrative bioinformatics in uncovering shared molecular mechanisms between seemingly distinct diseases. By revealing common gene signatures and pathways, it opens the door to repurposing existing drugs for comorbid conditions, potentially accelerating the development of more effective treatments for patients suffering from both RA and T2DM.

While the findings are promising, the study is based on computational predictions and will require experimental validation to confirm the efficacy and safety of the proposed drug candidates in clinical settings.

[[TRANSITION]]

Monoclonal antibodies are among the most promising tools for treating neurological disorders, thanks to their high specificity for target molecules. But there's a major problem: they don't get into the brain very well. The blood-brain barrier blocks most large molecules, and even when antibodies do cross, they spread poorly through the dense brain tissue. That's a huge limitation for treating conditions like Alzheimer's, brain tumors, or neurodegenerative diseases.

To address this, researchers have been developing nanocarriers—tiny delivery vehicles that can ferry antibodies across the BBB and improve their distribution inside the brain. The idea is to package the antibody in a structure that can either slip through the barrier more easily or be actively transported across it.

The available text doesn't specify which nanocarrier designs were tested or how they were made, but it does emphasize that the structure of these carriers matters a lot. Some designs may shield the antibody from degradation, others might target specific transport mechanisms at the BBB, and some could alter how the cargo diffuses once inside the brain. The key takeaway is that not all nanocarriers are created equal—small changes in size, surface chemistry, or shape can have big effects on delivery efficiency.

What's still unclear is which structural features actually work best, how much improvement they offer over naked antibodies, and whether these benefits translate to meaningful therapeutic outcomes in patients. The text also doesn't mention any specific diseases, animal models, or clinical data.

So while the concept is solid—use smarter packaging to get more antibody into the brain—the details on what "smarter" means in practice are still missing. That's the gap this research is trying to fill: figuring out exactly how nanocarrier structure influences both BBB crossing and brain distribution, so we can design delivery systems that actually make monoclonal antibody therapies viable for neurological disease.

[[TRANSITION]]

The urokinase-type plasminogen activator receptor, or uPAR, has emerged as a promising target for both diagnostic imaging and therapeutic applications in oncology. This receptor is overexpressed in many aggressive cancers, including breast, prostate, and lung cancers, making it an attractive biomarker for precision medicine approaches. The challenge, however, has been developing radiopeptides that can effectively target uPAR while also achieving optimal tissue distribution—specifically, minimizing unwanted accumulation in blood and non-target tissues while maximizing tumor uptake.

The core innovation in this work centers on a strategic modification to the albumin-binding moiety of previously developed uPAR-targeting radiopeptides. Earlier generations used a p-iodophenyl group to bind to serum albumin, which extended the circulation time of the radiopeptide but also led to prolonged blood retention—a drawback for both imaging clarity and therapeutic efficacy. The new approach replaces this with a p-tolyl group, connected via various linkers such as PEG3, PEG4, PEG5, or an aliphatic 8-aminooctanoic acid chain. Additionally, the researchers explored replacing the lysine residue with diaminopropionic acid and swapping the DOTA chelator for DOTAGA, aiming to fine-tune the pharmacokinetic profile.

Six novel peptides—uPAR-11, -12, -14, -15, -17, and -18—were synthesized using solid-phase peptide synthesis, purified by HPLC, and characterized by high-resolution mass spectrometry. The hypothesis was that these modifications would yield radiopeptides with reduced blood retention and improved tumor-to-background ratios, making them more suitable for therapeutic applications where minimizing off-target radiation is critical.

The available text does not provide details on the in vivo biodistribution or imaging results, so the actual performance of these new radiopeptides remains to be seen. However, the systematic approach—varying both the albumin-binding entity and the linker chemistry—represents a thoughtful strategy to optimize tissue distribution. If successful, these next-generation uPAR-targeting radiopeptides could offer a more favorable balance between tumor uptake and clearance from blood, potentially improving both diagnostic accuracy and therapeutic outcomes in cancer patients. The work underscores the importance of molecular design in radiopharmaceutical development and sets the stage for future studies to validate these promising modifications in preclinical and clinical settings.

[[TRANSITION]]

PCSK9 inhibitors are already well established for lowering LDL cholesterol and reducing cardiovascular risk, but a new narrative review in CNS Drugs suggests they may also have a powerful role in treating acute ischemic stroke through anti-inflammatory mechanisms.

The core idea is that PCSK9, beyond its lipid-regulating function, actively drives neuroinflammation after stroke. In acute ischemic stroke, the brain's inflammatory response becomes a major driver of secondary injury. This process involves microglial activation, infiltration of peripheral immune cells, cytokine storms, and oxidative stress—all of which amplify damage beyond the initial clot.

The review highlights that PCSK9 contributes to this inflammatory cascade through multiple pathways. It can activate microglia via ApoER2 signaling, promote vascular inflammation through the Lp(a)-TLR4 pathway, and trigger NF-κB signaling, a master regulator of inflammatory gene expression. These effects occur independently of PCSK9's role in LDL receptor degradation, meaning the protein has a distinct pro-inflammatory identity in the central nervous system.

The available text does not provide details on the specific anti-inflammatory mechanisms by which PCSK9 inhibitors might work in stroke, nor does it cite clinical trial data demonstrating efficacy in this context. However, the review synthesizes existing literature to argue that blocking PCSK9 could interrupt these inflammatory loops, potentially reducing secondary brain injury and improving outcomes.

This positions PCSK9 inhibitors as a novel immunomodulatory strategy for acute ischemic stroke—one that could complement existing reperfusion therapies by targeting the inflammatory aftermath rather than just the initial vascular occlusion. While the concept is compelling, the review is narrative in nature and does not present original experimental data, so clinical validation remains an open question.

[[TRANSITION]]

AHT-102 is a novel bispecific antibody targeting CLDN18.2 and CD3, designed to recruit and activate T cells specifically within CLDN18.2-expressing solid tumors. The antibody uses an XFab® platform with lower CD3 affinity, which the developers claim reduces the risk of cytokine release syndrome compared to conventional CD3-engaging bispecifics.

The pharmacokinetics were evaluated in humanized hCD3EDG mice after single intravenous doses of 0.1, 0.5, and 2.5 mg/kg. Serum concentrations were measured using electrochemiluminescence immunoassay at 11 timepoints from pre-dose to 24 hours post-injection. Non-compartmental analysis in Phoenix WinNonlin was used to calculate PK parameters and assess dose linearity.

The available text does not provide the actual PK parameter values, dose-normalized exposure data, or specific half-life estimates. It also does not detail the anti-tumor efficacy results, tissue distribution findings, or the complete safety profile including CRS incidence or severity grading.

The core innovation appears to be the XFab® platform's engineered lower CD3 affinity, which is intended to improve the therapeutic window by reducing systemic T cell activation while maintaining local tumor targeting. However, without the quantitative PK data, efficacy metrics, or safety outcomes, the actual performance characteristics and clinical differentiation remain unclear from the provided information.

[[TRANSITION]]

Leptospirosis is a bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. The disease can trigger a systemic inflammatory response syndrome, often driven by a cytokine storm during infection. While the clinical manifestations are well documented, the molecular mechanisms underlying these extensive inflammatory responses remain poorly understood.

A recent study published in Antonie van Leeuwenhoek has identified a key player in this process: the HtrA protease from Leptospira interrogans. HtrA proteases are serine proteases that function as both chaperones and proteases, often involved in protein quality control and stress responses. In pathogenic bacteria, they can also act as virulence factors by modulating host-pathogen interactions.

The researchers found that the L. interrogans HtrA protease is a potent inducer of multifaceted cellular responses. When exposed to this protease, host cells exhibited significant changes in gene expression, particularly in pathways related to inflammation, immune signaling, and cell death. The protease appeared to trigger the production of pro-inflammatory cytokines, contributing to the cytokine storm observed in severe leptospirosis cases.

Mechanistically, the study suggests that HtrA protease may cleave specific host proteins or activate signaling cascades that amplify the inflammatory response. This could explain how a single bacterial enzyme can have such a broad impact on host cell behavior. The findings also raise the possibility that HtrA protease could be a target for therapeutic intervention, potentially by blocking its activity or downstream signaling.

This work adds to a growing body of evidence that bacterial proteases are not just tools for nutrient acquisition but also sophisticated modulators of host immunity. In the case of Leptospira, the HtrA protease seems to play a central role in driving the pathological inflammation that characterizes severe disease. Understanding these mechanisms could open new avenues for treating leptospirosis and other spirochete infections.

[[TRANSITION]]

Calliandra harrisii, a plant native to the Americas, is emerging as a surprising source of next-generation antimicrobial agents. Researchers have turned to this medicinal plant to synthesize silver nanoparticles, then used computational modeling to explore how these particles might overcome multidrug resistance in Staphylococcus species.

The approach is entirely in silico—meaning everything happens on a computer rather than in a lab dish. Scientists first identified key resistance and virulence genes in Staphylococcus, including spa (which produces protein A, a molecule that helps bacteria evade the immune system), hld (encoding δ-hemolysin, a toxin), fmhA (involved in cell wall synthesis), and lukD (part of a pore-forming leukocidin toxin). Using molecular docking software like AutoDock Vina and visualization tools such as PyMOL, they simulated how C. harrisii-derived silver nanoparticles interact with the proteins these genes encode.

The modeling suggests the nanoparticles can bind to these targets, potentially disrupting the bacteria's ability to resist antibiotics or cause disease. This is significant because Staphylococcus species—especially methicillin-resistant S. aureus (MRSA)—are notorious for developing resistance to multiple drug classes, making infections extremely difficult to treat.

What makes this work compelling is the focus on natural products as a source of novel antimicrobials. Silver nanoparticles have shown broad-spectrum activity, and deriving them from medicinal plants could offer a sustainable, biocompatible alternative to synthetic drugs. The computational pipeline also allows researchers to screen potential interactions before committing to expensive lab experiments.

However, the findings remain theoretical. No actual antimicrobial testing—such as minimum inhibitory concentration assays or biofilm disruption studies—has been reported. The proposed mechanism, while plausible from a modeling standpoint, hasn't been confirmed through biochemical or microbiological experiments. There's also no data on whether these nanoparticles work against other Staphylococcus species or bacteria beyond the computational targets.

In short, this study opens a promising computational pathway for designing plant-derived silver nanoparticles to fight resistant Staphylococcus, but real-world efficacy and safety still need rigorous experimental validation.

[[TRANSITION]]

Protein structure prediction has undergone a dramatic transformation over the past decade, shifting from physics-based simulations to data-driven deep learning approaches that now rival experimental methods. The field's evolution reflects a fundamental change in how we approach the sequence-structure-function relationship in proteins.

Traditional methods relied heavily on molecular dynamics simulations using tools like AMBER and GROMACS, or homology modeling based on known structures. These approaches, while valuable, were computationally intensive and often struggled with proteins lacking close structural homologs. The breakthrough came with the application of deep learning architectures, particularly transformer-based models and geometric neural networks.

The most significant milestone was AlphaFold2's performance in the CASP14 competition, where it demonstrated that deep learning could solve the protein folding problem for single-domain proteins with unprecedented accuracy. This achievement wasn't isolated - it represented the culmination of several parallel developments in the field.

Protein language models emerged as a powerful tool, with models like ESM and ProtGPT2 trained on massive sequence databases to learn evolutionary and biophysical patterns. These models capture the implicit structural constraints embedded in protein sequences through evolutionary pressure. The key insight was that sequences from related proteins contain information about their three-dimensional structures, even when those structures aren't explicitly known.

Structure prediction networks like RoseTTAFold took this further by integrating multiple sequence alignments with geometric reasoning. These models use equivariant graph neural networks to predict pairwise residue distances and orientations, then assemble these predictions into full 3D coordinates. The geometric awareness is crucial - proteins exist in three-dimensional space, and models must respect the physical constraints of this space.

The integration of structure and function prediction represents another major advance. Graph convolutional networks applied directly to 3D protein structures enable accurate function prediction and model quality assessment. Multi-modal frameworks that combine sequence, structure, and textual biomedical data show improved performance on downstream tasks like binding affinity prediction and solubility assessment.

De novo protein design has also benefited enormously from these advances. Methods like RF diffusion use generative models to design novel protein backbones and sequences with desired functions. This opens up possibilities for creating proteins with properties not found in nature, potentially addressing challenges in medicine, materials science, and catalysis.

The impact extends beyond individual protein predictions. Evolutionary-scale language models trained on hundreds of millions of sequences can predict structure in a zero-shot manner and assess the effects of mutations on function. This capability is particularly valuable for understanding disease mechanisms and designing therapeutic interventions.

Benchmarks and databases like CATH and SCOP provide essential structural and functional annotations for training and evaluating these models. The availability of high-quality training data has been crucial for the success of deep learning approaches in this domain.

This paradigm shift enables accelerated basic research through rapid generation of high-confidence structural models for entire proteomes. In drug discovery, structure-based virtual screening and de novo design of binders become more efficient, particularly for targets lacking experimental structures. Protein engineering benefits from predictive models of mutation effects, allowing rational design of proteins with enhanced stability, activity, or novel functions.

The field continues to evolve rapidly, with new architectures and training strategies emerging regularly. The challenge now lies not just in predicting structures accurately, but in understanding the limitations of these predictions and developing methods that can handle the full complexity of protein behavior in biological systems.

[[TRANSITION]]

This study focuses on an endo-1,4-β-xylanase enzyme from Agrobacterium sp. strain DKPNP3, which was isolated from the gut of the beetle Gonocephalum sp. Xylanases are enzymes that break down xylan, a major component of plant hemicellulose, and are important both industrially and ecologically. The research aims to characterize this particular xylanase through structural and dynamic stability analysis using in silico methods.

The available text does not provide details on the specific methods or approaches used in the study, nor does it describe the key evidence or findings. It also does not explain why this research matters or what its limitations or uncertainties might be. Terms related to the study, such as "endo-1,4-β-xylanase," "hemicellulose," or "in silico analysis," are not defined in the provided text.

In summary, while the study appears to involve the structural and dynamic analysis of a xylanase enzyme from a beetle gut bacterium, the available text does not contain sufficient information to describe the methods, results, or significance of the work.

[[TRANSITION]]

RNA base editing has emerged as a promising tool for correcting mutations at the RNA level, but a major challenge has been widespread off-target effects. These off-targets primarily arise from dissociated free deaminases that remain active after editing. To address this, researchers have developed the RECODE system, which stands for RNA editing with conditionally stable and enhanced ADAR1 deaminase variants.

The RECODE system works by stabilizing the deaminase enzyme only when it is bound to its target RNA. This conditional stability ensures that the enzyme remains active only at the intended editing site, significantly reducing off-target activity. The approach leverages engineered ADAR1 deaminase variants that are inherently more precise and stable when engaged with their target.

This innovation represents a significant step forward in RNA editing technology. By tethering the deaminase's stability to its target engagement, RECODE minimizes the risk of unintended edits elsewhere in the transcriptome. This is particularly important for therapeutic applications where precision is critical.

The development of RECODE builds on earlier work in base editing but introduces a novel mechanism for controlling enzyme activity. Unlike previous approaches that relied solely on improving the intrinsic specificity of the deaminase, RECODE adds a layer of conditional control that acts as a safeguard against off-target effects.

While the available text does not provide specific details on the experimental validation or efficiency metrics of RECODE, the conceptual framework suggests a robust strategy for enhancing the fidelity of RNA base editing. This could have broad implications for treating genetic diseases caused by RNA mutations, where precise and safe editing is essential.

The RECODE system exemplifies how engineering protein stability can be harnessed to improve the safety and efficacy of gene editing tools. As RNA therapeutics continue to advance, innovations like this will be crucial for translating the promise of RNA editing into clinical reality.

[[TRANSITION]]

This paper from AAPS PharmSciTech addresses a practical challenge in bioanalytical method validation for therapeutic antibodies. The ICH M10 guideline, adopted by the EMA in 2022 and implemented in 2023, requires that stability testing of quality controls should match actual sample analyte concentrations. This means laboratories need to adjust their QC levels when samples exceed analytical ranges.

The core innovation here is using incurred sample reproducibility data to support long-term stability claims for therapeutic antibodies. Instead of running separate long-term stability studies on ultra-high concentration samples, which can be resource-intensive, the authors propose leveraging ISR data that's already collected during method validation.

ISR involves re-analyzing a portion of study samples to confirm original results are reproducible. By demonstrating that incurred samples remain stable across multiple analyses over time, laboratories can build a stronger case for long-term stability without conducting dedicated LTS studies on every concentration level.

This approach matters because therapeutic antibodies often have wide concentration ranges in clinical samples. Traditional QC-based stability testing might miss stability issues that only appear at the extremes of the analytical range. ISR data captures real-world sample behavior, including matrix effects and analyte-specific degradation patterns.

The method reduces redundancy in stability testing while maintaining regulatory compliance. It's particularly valuable for laboratories dealing with high-concentration samples where preparing stable QCs can be challenging. The approach aligns with the ICH M10 emphasis on method robustness and real sample behavior rather than idealized QC performance.

The available text doesn't provide specific implementation details, statistical approaches, or validation results. However, the conceptual framework represents a shift toward using existing validation data more efficiently while maintaining scientific rigor in stability assessment.

[[TRANSITION]]

This episode's deep dive is a bit unusual. The source material provided is not an article text but a list of references and bibliography entries. As a result, there is no core claim, method, key evidence, significance, limitations, or term definitions available from the provided input. The text does not contain the actual research findings or explanations that would typically be discussed in a deep dive segment. Therefore, it is not possible to create a detailed narrative about the research based solely on this bibliography. To proceed, the actual article text would be needed to extract the relevant scientific content and insights.

[[TRANSITION]]

Here's a deep-dive segment based on the available information:

This study explores the anticancer potential of rupestonic acid, a compound from Artemisia rupestris L., and its derivatives. The research team employed a systematic, multi-stage approach combining network pharmacology and molecular docking to identify and optimize promising anti-tumor agents.

The investigation began with network pharmacology analysis, which predicted rupestonic acid's polypharmacological mechanisms by mapping its interactions with 55 potential cancer-related targets. This computational approach helped identify key molecular pathways and biological processes that rupestonic acid might influence in cancer cells.

Building on these predictions, the researchers designed and synthesized a series of rupestonic acid derivatives. The goal was to enhance the compound's anticancer properties while potentially improving other characteristics like bioavailability or selectivity.

Molecular docking studies were then used to virtually screen these derivatives against the predicted target proteins. This computational technique helps predict how well a small molecule might bind to a specific protein target, providing insights into potential mechanisms of action and guiding the selection of the most promising candidates for experimental testing.

The most promising derivative identified through this integrated approach was then subjected to experimental evaluation. While the specific results of these experiments aren't detailed in the available text, such studies typically involve testing the compound's effects on cancer cell viability, proliferation, and other relevant biological endpoints.

This research represents a rational drug design strategy that combines computational predictions with experimental validation. By using network pharmacology and molecular docking to guide the design of rupestonic acid derivatives, the researchers aimed to accelerate the discovery of more effective anticancer agents while reducing the need for extensive trial-and-error experimentation.

The approach demonstrates how modern computational tools can be integrated with traditional medicinal chemistry to develop novel therapeutics, potentially offering new options for cancer treatment based on natural product scaffolds.

[[TRANSITION]]

NeuroPpred-MSN is a new computational model designed to predict neuropeptides more accurately by combining multiple types of biological features with a Siamese neural network architecture. The motivation behind this work is that neuropeptides are important signaling molecules in the nervous system, and they represent a promising but underexplored source of drug targets, especially those found in venoms. Traditional computational methods for identifying neuropeptides have had limited accuracy, so there's a clear need for better prediction tools.

The model works by fusing several different types of biological data—such as sequence information, physicochemical properties, and structural features—into a single, unified representation. This multi-feature fusion approach allows the model to capture more nuanced patterns that single-feature methods might miss. The Siamese network component is particularly interesting: it's a type of deep learning architecture that compares pairs of inputs to determine their similarity. In this context, it helps the model distinguish neuropeptides from non-neuropeptides more effectively by learning from pairs of peptides and their labels.

The available text doesn't provide specific performance metrics or comparisons to other models, so it's not possible to say exactly how much better NeuroPpred-MSN is than existing methods. However, the combination of multi-feature fusion and Siamese networks is a novel approach in this field, and the authors suggest it offers significant improvements in prediction accuracy.

This work is part of a broader trend in drug discovery that leverages advanced mass spectrometry-based peptidomics and AI-driven computational models. By improving the ability to identify and characterize neuropeptides, especially those from venom sources, NeuroPpred-MSN could help accelerate the discovery of new therapeutic targets and drugs. The integration of experimental peptidomics data with deep learning is a powerful strategy, and this model represents a step forward in making neuropeptide research more efficient and impactful.

[[TRANSITION]]

EMMVEP is a new computational method for predicting the effects of protein missense mutations. These mutations change a single amino acid in a protein and can have major impacts on protein function, sometimes leading to disease. The challenge is distinguishing which mutations are harmful from those that are harmless, and that's where EMMVEP comes in.

The method uses an ensemble approach, meaning it combines multiple machine learning models to improve prediction accuracy. It also incorporates multi-source feature fusion, which means it pulls in different types of biological and structural information about the protein and the mutation site to make its predictions. This is important because no single type of data tells the whole story about how a mutation might affect a protein.

The core innovation here is the integration of diverse data sources—such as evolutionary conservation, protein structure, and biochemical properties—into a unified prediction framework. By doing so, EMMVEP aims to capture more nuanced effects of mutations than methods relying on a single data type.

While the available text does not provide specific performance metrics or comparisons to existing tools, the approach is designed to address a key limitation in the field: the need for more accurate and comprehensive prediction of mutation effects. This is especially relevant for clinical applications, where distinguishing pathogenic variants from benign ones can guide diagnosis and treatment decisions.

The method likely builds on advances in machine learning and bioinformatics, but without access to the full details, it's not possible to say exactly which algorithms or datasets were used. The ensemble and multi-source fusion strategies suggest a robust design, but the true impact will depend on how well it performs in real-world testing.

In summary, EMMVEP represents a step toward more reliable prediction of protein missense variant effects by combining multiple data sources and machine learning models. This could help researchers and clinicians better understand the functional consequences of genetic mutations, though further validation is needed to confirm its effectiveness.

[[TRANSITION]]

Here's what we know from the available text: The provided input is a list of bibliographic references, not the full text of a specific article. As a result, there is no core claim, method, key evidence, significance, limitations, or explanatory terms to report from a primary study.

The bibliography includes citations to various works on poliovirus, vaccine development, structural biology, and related topics, but without the full text of the source article, it's impossible to extract the specific findings, methods, or conclusions of the study in question.

To create a meaningful deep-dive segment, we would need the actual full text of the article to understand what new insights were gained about polio type 1 stabilized virus-like particles, what structural details were elucidated, and what implications these findings have for vaccine development.

The available text does not provide details on the specific structural insights, assembly mechanisms, or D antigenicity findings that would be central to understanding this research. Without access to the primary source material, any discussion would be speculative rather than factual.

For accurate reporting on this topic, the full text of the original research article would need to be obtained and analyzed.

[[TRANSITION]]

Doug Ingram's tenure at Sarepta Therapeutics left a mixed legacy, according to Endpoints News. The article examines his leadership during a period of both significant advances and controversies at the biotech firm. Meanwhile, Merck announced a major restructuring of its human health business, splitting it into two distinct units: one focused on oncology and another on specialty pharmaceuticals and infectious diseases. As part of this reorganization, Merck has brought in a senior executive from Sanofi to lead the new structure. These parallel developments highlight ongoing shifts in the pharmaceutical industry, with companies reassessing their strategic focus and leadership to better position themselves in competitive therapeutic areas.

[[TRANSITION]]

The European Medicines Agency's CHMP has recommended approval for six new medicines, including Moderna's combined influenza and Covid-19 vaccine and Novartis's oral treatment for hives. This recommendation marks a crucial step toward EU marketing authorization for these therapies. If approved, the Moderna vaccine would offer a single-shot solution for both respiratory illnesses, while Novartis's pill would provide a new oral option for managing urticaria. The CHMP's positive opinion will now be reviewed by the European Commission for final authorization. Endpoints News reports this development as part of the EMA's ongoing evaluation of innovative treatments for European patients.


References:
[1] Coral microbiomes as reservoirs of unknown genomic and biosynthetic diversity — Nature (main journal) — https://www.nature.com/articles/s41586-026-10159-6
[2] Clonal-aggregative multicellularity tuned by salinity in a choanoflagellate — Nature (main journal) — https://www.nature.com/articles/s41586-026-10137-y
[3] OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours — Nature (main journal) — https://www.nature.com/articles/s41586-026-10149-8
[4] Data storage and retrieval with unnatural proteins expressed via E. coli — Nature - Protein Design — https://www.nature.com/articles/s41467-026-70061-7
[5] Intermittent fasting evicts long-lived plasma cells from survival niche — Nature - Antibodies — https://www.nature.com/articles/s41577-026-01286-2
[6] The endoplasmic reticulum in mitochondrial protein targeting: A neuronal perspective on organelle crosstalk — Protein Science — https://onlinelibrary.wiley.com/doi/10.1002/pro.70506?af=R
[7] Deamidation and isomerization to elusive isoaspartate in a computationally designed miniprotein. — PubMed — Protein science : a publication of the Protein Society — https://doi.org/10.1002/pro.70508
[8] MemPPI platform for measuring and engineering membrane protein-protein interactions in mammalian cells via split nanoluciferase. — PubMed — Protein science : a publication of the Protein Society — https://doi.org/10.1002/pro.70496
[9] Discovery of novel, high-affinity HBV T-cell epitopes by molecular dynamics-augmented proteome-wide screening. — PubMed — Protein science : a publication of the Protein Society — https://doi.org/10.1002/pro.70503
[10] Designing a novel vaccine against COVID-19 based on spike SARS-Cov-2 notable mutations using immunoinformatics approaches. — PubMed — PloS one — https://doi.org/10.1371/journal.pone.0334662
[11] Graph Learning in Bioinformatics: A Survey of Graph Neural Network Architectures, Biological Graph Construction and Bioinformatics Applications. — PubMed — Biomolecules — https://doi.org/10.3390/biom16020333
[12] Characterization of Conformational Instability of Monoclonal Antibodies During Chromatographic Purification. — PubMed — International journal of molecular sciences — https://doi.org/10.3390/ijms27042064
[13] Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities. — PubMed — Molecules (Basel, Switzerland) — https://doi.org/10.3390/molecules31040753
[14] Peptide-functionalized nanoparticles for brain-targeted therapeutics. — PubMed — Drug delivery and translational research — https://doi.org/10.1007/s13346-025-01840-w
[15] Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination. — PubMed — JCI insight — https://doi.org/10.1172/jci.insight.199245
[16] TRIM13 in situ engineering boosts anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy. — PubMed — Nature communications — https://doi.org/10.1038/s41467-026-69858-3
[17] Exploring the shared gene signatures between rheumatoid arthritis and type 2 diabetes and their implication for drug repositioning on bioinformatics analysis. — PubMed — Medicine — https://doi.org/10.1097/MD.0000000000047809
[18] Delivery of monoclonal antibodies to the brain: the impact of nanocarrier structure. — PubMed — Drug delivery and translational research — https://doi.org/10.1007/s13346-025-01957-y
[19] Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy. — PubMed — European journal of nuclear medicine and molecular imaging — https://doi.org/10.1007/s00259-025-07602-7
[20] Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke. — PubMed — CNS drugs — https://doi.org/10.1007/s40263-026-01278-9
[21] Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile. — PubMed — Drugs in R&D — https://doi.org/10.1007/s40268-026-00535-y
[22] Leptospira interrogans HtrA protease is a potent inducer of multifaceted cellular responses. — PubMed — Antonie van Leeuwenhoek — https://doi.org/10.1007/s10482-026-02270-5
[23] Structure-based drug discovery targeting — PubMed — Zeitschrift fur Naturforschung. C, Journal of biosciences — https://doi.org/10.1515/znc-2025-0274
[24] CPE-Pro: A Structure-Sensitive Deep Learning Method for Protein Representation and Origin Evaluation. — PubMed — Interdisciplinary sciences, computational life sciences — https://doi.org/10.1007/s12539-025-00732-4
[25] In silico structural and dynamic stability analysis of an endo-1,4-β-xylanase from Agrobacterium sp. strain DKPNP3, isolated from the gut of Gonocephalum sp. — PubMed — Antonie van Leeuwenhoek — https://doi.org/10.1007/s10482-026-02271-4
[26] Target-stabilized base editors enable robust high-fidelity RNA editing. — PubMed — Nature communications — https://doi.org/10.1038/s41467-026-69835-w
[27] Use of Incurred Sample Reproducibility Data to Support Long Term Stability of Therapeutic Antibodies in Clinical Bioanalytical Methods. — PubMed — AAPS PharmSciTech — https://doi.org/10.1208/s12249-026-03336-3
[28] ISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer. — PubMed — Cell death & disease — https://doi.org/10.1038/s41419-026-08527-1
[29] Design, synthesis, and experimental evaluation of rupestonic acid derivatives as novel anti-tumor agents guided by network pharmacology and molecular docking. — PubMed — Scientific reports — https://doi.org/10.1038/s41598-026-39442-2
[30] NeuroPpred-MSN: A Neuropeptide Prediction Model Based on Multi-feature Fusion and Siamese Networks. — PubMed — Interdisciplinary sciences, computational life sciences — https://doi.org/10.1007/s12539-025-00730-6
[31] EMMVEP: An Ensemble Method for Protein Missense Variant Effect Prediction Based on Multi-Source Feature Fusion. — PubMed — Interdisciplinary sciences, computational life sciences — https://doi.org/10.1007/s12539-025-00812-5
[32] Structural insight into the assembly and D antigenicity of polio type 1 stabilized virus-like particles. — PubMed — NPJ vaccines — https://doi.org/10.1038/s41541-026-01404-0
[33] Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi exec — Endpoints News — https://endpoints.news/doug-ingrams-uneven-legacy-at-sarepta-merck-splits-human-health-business-brings-in-sanofi-exec/
[34] CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives — Endpoints News — https://endpoints.news/chmp-recommends-modernas-flu-covid-shot-and-novartis-pill-for-hives/
